Skip to main content
SpringerLink
Log in

The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF), collectively known as Philadelphia-negative (Ph-negative) chronic myeloproliferative neoplasms (MPNs), MPNs represent the most common causes of splanchnic vein thrombosis (SVT), including Budd-Chiari syndrome (BCS) and portal vein thrombosis (PVT). The JAK2V617F mutation has been demonstrated in most of the Ph-negative chronic MPNs. The study objective was to assess the diagnostic value of JAK2V617F mutation in patients with SVT in a group of 68 patients with SVT (42 PVT,19 BCS, 7 combined PVT and BCS). By DNA-melting curve analysis, the JAK2V617F mutation was detected in 42.1 % of BCS, 38.1 % of PVT and 71.4 % of combined PVT and BCS groups. Thirteen of 15 (86.6 %) SVT patients with overt MPN and 16 of 53 (30.1 %) SVT patients without overt MPN (patients with either normal blood counts or cytopenias), including 6 of 16 with BCS (37.5 %), 7 of 33 with PVT (21.2 %) and 3 of 4 with combined BCS and PVT (75 %) possessed JAK2V617F mutation. A substantial proportion of patients with SVT were recognized as carriers of the JAK2V617F mutation despite the absence of overt signs of MPN. Receiver Operating Characteristic (ROC) curve analysis determined a platelet count of 190,000 mm3 (area under the curve; AUC = 0.724, p = 0.002) and a white blood cell (WBC) count of 8,150 mm3 (AUC = 0.76, p = 0.001) as the best cut-off values for the highest sensitivity and specificity ratios of the JAK2V617F mutation in patients with SVT. A significant positive correlation existed between the JAK2V617F mutational status of SVT patients and the WBC and platelet counts. Our results imply that JAK2V617F mutation screening should be an initial test for MPN in patients with SVT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061

    PubMed  CAS  Google Scholar 

  2. James C, Ugo V, Le Couedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148

    Article  PubMed  CAS  Google Scholar 

  3. Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790

    Article  PubMed  CAS  Google Scholar 

  4. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397

    Article  PubMed  CAS  Google Scholar 

  5. De Stefano V, Za T, Rossi E, GIMEMA CMD-Working Party et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93:372–380

    Article  PubMed  Google Scholar 

  6. Gruppo Italiano Studio Policitemia (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 123:656–664

    Google Scholar 

  7. De Stefano V, Teofili L, Leone G, Michiels JJ (1997) Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 23:411–418

    Article  PubMed  Google Scholar 

  8. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC (2003) Budd-Chiari syndrome: a review by an expert panel. J Hepatol 38:364–371

    Article  PubMed  Google Scholar 

  9. Anger B, Haugh U, Seidler R, Heimpel H (1989) Polycythemia vera: a clinical study of 141 patients. Blut 59(6):493–500

    Article  PubMed  CAS  Google Scholar 

  10. Teofili L, De Stefano V, Leone G, Micalizzi P, Iovino MS, Alfano G, Bizzi B (1992) Hematologic causes of venous thrombosis in young people: high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis. Thromb Haemost 67(3):297–301

    PubMed  CAS  Google Scholar 

  11. Murad SD, Plessier A, Hernadez-Guerra M et al (2009) Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 151:167

    Google Scholar 

  12. Hirshberg B, Shouval D, Fibach E et al (2000) Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome. J Hepatol 32:574

    Article  PubMed  CAS  Google Scholar 

  13. Primignani M, Barosi G, Bergamaschi G et al (2006) Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 44(6):1528–1534

    Article  PubMed  CAS  Google Scholar 

  14. Valla D, Casadevall N, Huisse MG et al (1988) Etiology of portal vein thrombosis in adults: a prospective evaluation of primary myeloproliferative disorders. Gastroenterology 94:1063–1069

    PubMed  CAS  Google Scholar 

  15. Belli L, Romani F, Riolo F et al (1989) Thrombosis of portal vein in absence of hepatic disease. Surg Gynecol Obstet 169:46

    PubMed  CAS  Google Scholar 

  16. Plessier A, Darwish-Murad S, Hernandez-Guerra M et al (2010) Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 51:210

    Article  PubMed  Google Scholar 

  17. Aster RH (1966) Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest 45:645

    Article  PubMed  CAS  Google Scholar 

  18. Schmidt KG, Rasmussen JW, Bekker C, Madsen PE (1985) Kinetics and in vivo distribution of 111-In-labelled autologous platelets in chronic hepatic disease: mechanisms of thrombocytopenia. Scand J Haematol 34(1):39–46

    Article  PubMed  CAS  Google Scholar 

  19. Chung RT, Iafrate AJ, Amrein PC, Sahani DV, Misdraji J (2006) Case records of the Massachusetts General Hospital. Case 15-2006: a 46-year-old woman with sudden onset of abdominal distention. N Engl J Med 354:2166–2175

    Article  PubMed  CAS  Google Scholar 

  20. Menon KV, Shah V, Kamath PS (2004) The Budd-Chiari syndrome. N Engl J Med 350:578–585

    Article  PubMed  CAS  Google Scholar 

  21. Valla D, Casadevall N, Lacombe C et al (1985) Primary myeloproliferative disorder and hepatic vein thrombosis: a prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 103:329–334

    PubMed  CAS  Google Scholar 

  22. Boissinot M, Lippert E, Girodon F, Dobo I, Fouassier M, Masliah C, Praloran V, Hermouet S et al (2006) Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 108(9):3223–3224

    Article  PubMed  CAS  Google Scholar 

  23. Chait Y, Condat B, Cazals-Hatem D et al (2005) Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 129:553–560

    Article  PubMed  Google Scholar 

  24. Michiels JJ, Thiele J (2002) Clinical and pathologic criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 76:133–145

    Article  PubMed  Google Scholar 

  25. Patel RK, Lea NC, Heneghan MA et al (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130:2031–2038

    Article  PubMed  CAS  Google Scholar 

  26. Smalberg JH, Murad SD, Braakman E, Valk PJ, Janssen HL, Leebeek FW (2006) Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 91:1712–1713

    PubMed  Google Scholar 

  27. Spivak JL, Moliterno AR, Silver RT (2006) Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2. N Engl J Med 355(7):737 author reply 738

    Article  PubMed  CAS  Google Scholar 

  28. Kiladjian JJ, Cervantes F, Leebeek FW et al (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111:4922–4929

    Article  PubMed  CAS  Google Scholar 

  29. Colaizzo D, Amitrano L, Iannaccone L et al (2007) Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 44(6):412–416 Epub 2007 Feb 16

    Article  PubMed  CAS  Google Scholar 

  30. Regina S, Herault O, D’Alteroche L, Binet C, Gruel Y (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 5(4):859–861

    Article  PubMed  CAS  Google Scholar 

  31. Condat B, Pessione F, Hillaire S et al (2001) Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 120:490–497

    Article  PubMed  CAS  Google Scholar 

  32. DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver Diseases (2009) Vascular disorders of the liver. Hepatology 49(5):1729–1764

    Article  PubMed  CAS  Google Scholar 

  33. Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14–22

    Article  PubMed  CAS  Google Scholar 

  34. James C, Delhommeau F, Marzac C et al (2006) Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 20:350–353

    Article  PubMed  CAS  Google Scholar 

  35. Kiladjian JJ, Cassinat B, Turlure P et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037–2040

    Article  PubMed  CAS  Google Scholar 

  36. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39(4):561–577

    PubMed  CAS  Google Scholar 

  37. Steensma D, Dewald GW, Lasho TL et al (2005) The JAK2 tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207

    Article  PubMed  CAS  Google Scholar 

  38. Jelinek J, Oki Y, Gharibyan V et al (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106:3370

    Article  PubMed  CAS  Google Scholar 

  39. Levine RL, Loriaux M, Huntly BJ et al (2005) The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106:3377

    Article  PubMed  CAS  Google Scholar 

  40. Dilawari JB, Bambery P, Chawla Y et al (1994) Hepatic outflow obstruction (Budd-Chiari syndrome): experience with 177 patients and a review of the literature. Medicine 73:21

    Article  PubMed  CAS  Google Scholar 

  41. Case records of the Massachusetts General Hospital (1987) Weekly clinicopathological exercises. Case 51-1987. Progressive abdominal distention in a 51-year-old woman with polycythemia vera. N Engl J Med 317(25):1587–1596

    Article  Google Scholar 

  42. Mitchell MC, Boitnott JK, Kaufman S et al (1982) Budd-Chiari syndrome: etiology, diagnosis and management. Medicine (Baltimore) 61:199

    CAS  Google Scholar 

  43. Powell-Jackson PR, Melia W, Canalese J, Pickford RB, Portmann B, Williams R (1982) Budd-Chiari Syndrome: clinical patterns and therapy. Q J Med 51(201):79–88

    PubMed  CAS  Google Scholar 

  44. Gupta S, Blumgart LH, Hodgson HJF (1986) Budd-Chiari syndrome: long-term survival and factors affecting mortality. Q J Med 60:781

    PubMed  CAS  Google Scholar 

  45. Murphy FB, Steinberg HV, Shires GI III et al (1986) The Budd-Chiari syndrome: a review. AJR Am J Roentgenol 147:9

    PubMed  CAS  Google Scholar 

  46. Maddrey WC (1984) Hepatic vein thrombosis (Budd-Chiari syndrome). Hepatology 4:445

    Article  Google Scholar 

  47. Murad SD, Valla DC, De Groen PC et al (2004) Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 39:500

    Article  Google Scholar 

  48. De Stefano V, Fiorini A, Rossi E et al (2007) Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 5:708–714

    Article  PubMed  Google Scholar 

  49. Colaizzo D, Amitrano L, Tiscia GL et al (2007) The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5:55–61

    Article  PubMed  CAS  Google Scholar 

  50. Plume G, Vaya A, Ferrando F et al (2007) JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation. Thromb Haemost 98:681–682

    PubMed  CAS  Google Scholar 

  51. de Franchis R (2005) Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 43(1):167–176

    Article  PubMed  Google Scholar 

  52. Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, Grandi AM, Ageno W (2009) JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113(22):5617–5623 Epub 2009 Mar 9

    Article  PubMed  CAS  Google Scholar 

  53. Hexner EO (2007) JAK2 V617F: implications for thrombosis in myeloproliferative diseases. Curr Opin Hematol 14:450–454

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey

    Ipek Yonal & Meliha Nalcaci

  2. Division of Gastroenterohepatology, Department of Internal Medicine, Medical Faculty, Istanbul University, Istanbul, Turkey

    Binnur Pinarbası & Sabahattin Kaymakoglu

  3. Division of Hematology, Department of Internal Medicine, Istanbul Bilim University, Istanbul, Turkey

    Fehmi Hindilerden, Veysel Sabri Hancer & Reyhan Diz-Kucukkaya

Authors
  1. Ipek Yonal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Binnur Pinarbası
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fehmi Hindilerden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Veysel Sabri Hancer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meliha Nalcaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sabahattin Kaymakoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Reyhan Diz-Kucukkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ipek Yonal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yonal, I., Pinarbası, B., Hindilerden, F. et al. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. J Thromb Thrombolysis 34, 388–396 (2012). https://doi.org/10.1007/s11239-012-0738-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-012-0738-2

Keywords

Search

Navigation